Subsequent studies found a fourfold increase in risk of myocardial infarction (MI) for rofecoxib (Vioxx) users compared to naproxen users (ans-NSAID) [7], an excess of CVD events in trials of COX-2 efficacy in preventing recurrent colonic polyps [8,9], and a greater risk of coronary heart disease for high-dose rofecoxib (> 25 mg/day) users in observational studies [10]. The gene discussed is PTGS2; the disease is myocardial infarction.